Abstract
The unconstrained growth rate of COVID-19 is crucial for measuring the impact of interventions, assessing worst-case scenarios, and calibrating mathematical models for policy planning. However, robust estimates are limited, with scientific focus on the time-insensitive basic reproduction number R0. Using multiple countries, data streams and methods, we consistently estimate that European COVID-19 cases doubled every three days when unconstrained, with the impact of physical distancing interventions typically seen about nine days after implementation, during which time cases grew eight-fold. The combination of fast growth and long detection delays explains the struggle in countries’ response better than large values of R0 alone, and warns against relaxing physical distancing measures too quickly. Testing and tracing are fundamental in shortening such delays, thus preventing cases from escalating unnoticed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
LP, HS and CO are funded by the Wellcome Trust and the Royal Society (grant 202562/Z/16/Z). KL is funded by the Wellcome Trust and Royal Society (107652/Z/15/Z). FS is funded by the CIHR 2019 Novel Coronavirus (COVID-19) rapid research program, and is a member of the INdAM Research group GNCS. LC is funded by the BBSRC (grant BB/R009236/1). EF is funded by the MRC (grant MR/S020462/1). TH is supported by the Royal Society (Grant Number INF\R2\180067) and Alan Turing Institute for Data Science and Artificial Intelligence. IH is supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response and the National Institute for Health Research Policy Research Programme in Operational Research (OPERA) and Alan Turing Institute for Data Science and Artificial Intelligence. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code used in this analysis are provided in the Github repository (https://github.com/thomasallanhouse/covid19-growth), with the exception of the UK onset-to-hospitalisation delay data. These data are provided by Public Health England under a data sharing agreement, and we are unable to share them.
